Rapid Micro Biosystems secures US$32.6m in Series B Financing
Funding will be used to expand manufacturing operations in support of the Growth Direct system for environmental monitoring, sterility and bioburden testing
Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection for quality control testing within the pharmaceutical and personal care products market segments, has raised $32.6m in series B financing.
The funding will be used to expand the commercial and manufacturing operations in support of the Growth Direct System and the companion applications including: environmental monitoring, sterility and bioburden testing. Providing faster results from quality control testing allows drugs to be produced and released more quickly, economically and safely.
The Growth Direct is the only system on the market where all the applications can be run both concurrently and automatically on a single instrument. The system provides results starting within just hours, sending problem alerts so that decision-making and remedial action can start immediately. Leveraging an already proven detection technology, the Growth Direct delivers exceptional enhancements to productivity, faster response time and reduction in errors, the company says.
